E968

E968

SCHEMBL578415

CCOCC.OCC(O)C(O)CO

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
LMNA P02545 4/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TDP1 Q9NUW8 2/20 0.40
KDM4E B2RXH2 3/20 0.35
USP2 O75604 1/20 0.33
TSHR P16473 3/20 0.32
HSD17B10 Q99714 1/20 0.31
CYP2D6 P10635 2/20 0.30
SPHK1 Q9NYA1 1/20 0.30
GMNN O75496 1/20 0.30
POLB P06746 1/20 0.30
THPO P40225 1/20 0.30
MTOR P42345 1/20 0.30
BLM P54132 1/20 0.30
TP53 P04637 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
MAPT P10636 1/20 0.30
CETP P11597 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ether SCHEMBL1854464 0.92 ALDH1A1 (0.38) ALDH1A1LMNAL3MBTL1TDP1KDM4E
E968 SCHEMBL3916788 0.89 USP2 (0.42) ALDH1A1LMNAL3MBTL1TDP1KDM4E
Xylitol SCHEMBL20561020 0.88 LMNA (0.53) ALDH1A1LMNAL3MBTL1TDP1KDM4E
Mannitol SCHEMBL11015104 0.88 LMNA (0.61) ALDH1A1LMNAL3MBTL1TDP1KDM4E
Mannitol SCHEMBL3909131 0.88 LMNA (0.61) ALDH1A1LMNAL3MBTL1TDP1KDM4E
Sorbitol SCHEMBL619756 0.88 LMNA (0.61) ALDH1A1LMNAL3MBTL1TDP1KDM4E
Ribitol SCHEMBL3904172 0.88 LMNA (0.53) ALDH1A1LMNAL3MBTL1TDP1KDM4E
SCHEMBL15013779 0.86 ALDH1A1 (0.43) ALDH1A1LMNAL3MBTL1TDP1KDM4E
SCHEMBL22289432 0.86 ALDH1A1 (0.43) ALDH1A1LMNAL3MBTL1TDP1KDM4E
Ether SCHEMBL28205262 0.86 TDP1 (0.38) ALDH1A1LMNAL3MBTL1TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111393956-B Water-based two-component conversion type rusty anticorrosive paint and preparation thereof 中电保力(北京)科技有限公司 2021-08-20 CN claimed
CN-111393956-A Water-based two-component conversion type rusty anticorrosive paint and preparation thereof 中电保力(北京)科技有限公司 2020-07-10 CN claimed
EP-0912546-A1 IMPROVED RESERVOIR COMPONENTS AUSTRALIAN MEMBRANE AND BIOTECHNOLOGY RESEARCH INSTITUTE (AU) 1999-05-06 EP claimed
WO-1997043274-A1 IMPROVED RESERVOIR COMPONENTS AUSTRALIAN MEMBRANE AND BIOTECHNOLOGY RESEARCH INSTITUTE (AU) 1997-11-20 WO claimed
WO-2024142849-A1 WATER-IN-OIL EMULSION COSMETIC COMPOSITION 株式会社 資生堂 2024-07-04 WO disclosed
CN-117159398-B Super-fluid compound sun-screening agent and oil-in-water-in-oil triple sun-screening emulsion 广州嘉瑞新材料有限公司 2024-05-31 CN disclosed
US-11964043-B2 Method of emulsification using core-corona type microparticles SHISEIDO COMPANY, LTD. (JP) 2024-04-23 US disclosed
US-11931448-B2 Water-in-oil type emulsion composition SHISEIDO COMPANY, LTD. (JP) 2024-03-19 US disclosed
CN-117500478-A Hair care composition comprising hydroxylated triglyceride oligomers 宝洁公司 2024-02-02 CN disclosed
CN-117460490-A Skin external composition containing taurine crystal with useful component 考司美德制药株式会社 2024-01-26 CN disclosed
CN-117377454-A Skin care composition 考司美德制药株式会社 2024-01-09 CN disclosed
EP-3520772-B1 COSMETIC RAW MATERIAL USING CORE-CORONA TYPE MICROPARTICLES AND OIL-IN-WATER TYPE EMULSION COSMETIC SHISEIDO CO LTD (JP) 2023-12-20 EP disclosed
EP-1430905-A1 EXTERNAL PREPARATION FOR THE SKIN SHISEIDO COMPANY LIMITED (JP) 2004-06-23 EP disclosed
US-6607736-B2 Endermic liniment comprising diethoxy ethyl succinate and humectant SHISEIDO COMPANY, LTD. (JP) 2003-08-19 US disclosed
US-20030091603-A1 Skin preparations for external use SHISEIDO COMPANY, LTD. (JP) 2003-05-15 US disclosed
EP-1230026-A1 ION EXCHANGE RESINS AND METHODS OF MAKING THE SAME BASF AKTIENGESELLSCHAFT (DE) 2002-08-14 EP disclosed
US-6417009-B1 COUPLING LIPID AUSTRALIAN MEMBRANE AND BIOTECHNOLOGY INSTITUTE (AU) 2002-07-09 US disclosed
EP-1153602-A1 SKIN PREPARATIONS FOR EXTERNAL USE SHISEIDO COMPANY LIMITED (JP) 2001-11-14 EP disclosed
WO-2001030495-A1 ION EXCHANGE RESINS AND METHODS OF MAKING THE SAME BASF AKTIENGESELLSCHAFT (DE) 2001-05-03 WO disclosed
US-4351738-A ETHYLENE OXIDE-PROPYLENE OXIDE COPOLYMER TEIJIN LIMITED (JP) 1982-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030091603-A1 Skin preparations for external use CUTA, POLR1C, ACMSD ALDH1A1 473/4885LMNA 524/4885L3MBTL1 490/4885
US-11964043-B2 Method of emulsification using core-corona type microparticles LIPA, CORO1A, CLTA ALDH1A1 1811/4885LMNA 360/4885L3MBTL1 4505/4885
US-11931448-B2 Water-in-oil type emulsion composition FAM83A, LIPA, CUTA ALDH1A1 4446/4885LMNA 154/4885L3MBTL1 1865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.